Tamoxifen use reduces the risk of osteoporotic fractures in women with breast cancer in Asia: a nationwide population-based cohort study

Table 4 Adjusted hazard ratios (HRs) and 95 % confidence intervals (CIs) for different fracture locations in the time-dependent model among age group

Age group	Tamoxifen user vs. non-user HR (95 % CI)		p-value	Interaction p
Overall				0.29
<50	0.54	(0.36-0.82)	0.004
50-59	0.58	(0.40-0.83)	0.003
60-69	0.66	(0.50-0.88)	0.005
70+	0.59	(0.48-0.74)	<0.0001
Hip fracture				0.046
<50	0.39	(0.19-0.81)	0.01
50-59	0.38	(0.20-0.72)	0.003
60-69	0.56	(0.38-0.81)	0.002
70+	0.61	(0.47-0.78)	0.0001
Vertebral fracture				0.86
<50	0.59	(0.34-1.03)	0.06
50-59	0.74	(0.46-1.19)	0.21
60-69	0.84	(0.54-1.32)	0.46
70+	0.54	(0.34-0.85)	0.008
Wrist fracture				0.26
<50	0.90	(0.31-2.57)	0.84
50-59	0.76	(0.25-2.34)	0.63
60-69	1.44	(0.20-10.6)	0.72
70+	1.10	(0.07-17.9)	0.94

Manually adjusted for monthly income, comorbidity and aromatase inhibitor use before the end point